43 patents
Utility
USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
30 Nov 23
Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures.
Gary Hattersley
Filed: 6 Apr 23
Utility
Process of Making Abaloparatide
23 Nov 23
Disclosed herein is an improved process for preparing abaloparatide.
Matt Burke, Silvio Campagna
Filed: 19 May 23
Utility
Polymorphic Forms of RAD1901-2HCL
23 Nov 23
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized.
Michael Paul Cruskie, JR., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Filed: 31 May 23
Utility
Treatment of Long Bone Fractures with Abaloparatide
2 Nov 23
Provided herein are methods of accelerating long bone fracture healing that include daily administration of a therapeutically effective amount of abaloparatide in combination with a surgical intervention for a long bone fracture.
Beate Klara Maria Mannstadt, Bruce Mitlak
Filed: 3 Jul 23
Utility
Methods of Stimulating Bone Growth with Abaloparatide and Denosumab
19 Oct 23
Provided herein are methods for increasing bone mineral density, treating osteoporosis and the like, that include administration of abaloparatide in combination with denosumab.
Gary Hattersley, John A. Yates, Bruce Mitlak
Filed: 22 Jul 22
Utility
USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
12 Oct 23
Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures.
Gary Hattersley
Filed: 19 May 23
Utility
FORMULATIONS OF PTHrP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF
7 Sep 23
Disclosed are PTHrP analogue formulations for transdermal delivery of a therapeutically effective amount of a PTHrP analogue, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.
Gary Hattersley, Alan Harris, Jamal Saeh, Ehab Hamed, Kenneth Brown, Daniel Dohmeier, Joan Moseman, Ying Zhang, Lisa Dick
Filed: 4 Nov 22
Utility
Abaloparatide Formulations and Methods of Testing, Storing, Modifying, and Using Same
7 Sep 23
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers.
Greg Williams, Naveen Palwai, David Hanley
Filed: 22 Mar 23
Utility
Methods for Detecting Neutralizing Antibodies to Parathyroid Hormone (PTH) and Parathyroid Hormone-related Peptide (PTHRP) Analog
31 Aug 23
The present disclosure is directed to methods (e.g., in vitro methods) for detecting the presence of neutralizing antibodies to PTH or PTHrP analog in a sample.
Heidi K. Chandler
Filed: 5 May 23
Utility
Methods for Treating Ovarian Cancer
27 Apr 23
Methods of treating ovarian cancer are disclosed.
Gary HATTERSLEY
Filed: 27 Dec 22
Utility
Abaloparatide Formulations and Methods of Testing, Storing, Modifying, and Using Same
23 Feb 23
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers.
Greg Williams, Naveen Palwai, David Hanley
Filed: 21 Oct 22
Utility
Treatment and Prevention of Osteoporosis In High Body Mass Index Individuals
1 Dec 22
Disclosed herein is a method for preventing or reducing bone fractures in an overweight subject.
Elena Nikonova, Yamei Wang
Filed: 25 May 22
Utility
Methods for Treating Cancer
27 Oct 22
Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and RAD1901.
Gary HATTERSLEY
Filed: 29 Jun 22
Utility
Estrogen Receptor-modulating Compounds
20 Oct 22
Described herein are compounds that are estrogen receptor modulators.
Chris MILLER
Filed: 31 May 22
Utility
Stable Cannabinoid Formulations
8 Sep 22
The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
Filed: 18 Feb 22
Utility
Estrogen Receptor-modulating Compounds
8 Sep 22
Described herein are compounds that are estrogen receptor modulators.
Chris P. MILLER
Filed: 21 Jul 20
Utility
Methods for Detecting Neutralizing Antibodies to Parathyroid Hormone (PTH) and Parathyroid Hormone-related Peptide (PTHRP) Analog
30 Jun 22
The present disclosure is directed to methods (e.g., in vitro methods) for detecting the presence of neutralizing antibodies to PTH or PTHrP analog in a sample.
Heidi K. Chandler
Filed: 7 Jan 22
Utility
Methods of Improving Spinal Fusion with Abaloparatide
23 Jun 22
Provided herein are methods of enhancing spinal fusion and bone formation in subjects with spinal fractures, deformities or instability in the spine.
Beate Klara Maria Mannstadt, Bruce Mitlak
Filed: 11 Mar 22
Utility
Stable Cannabinoid Formulations
16 Jun 22
The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
Kiran Kumar VANGARA, Huaguang LI, Ningxin YAN, Hung Q. Nguyen, Venkat R. GOSKONDA
Filed: 22 Dec 21
Utility
Processes and Compounds
26 May 22
Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.
Michael MARKEY
Filed: 11 Feb 20